-
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at... -
Caregivers: Planning the Self-Care Journey
This webinar explains the phases of the caregiving cycle and offers tips and strategies for meeting the challenges of each phase. The discussion features Michelle Bolden, founder... -
Diving Deeper: Targeted Therapy, Radiation, and Immunotherapy
Lung cancer experts from Johns Hopkins Kimmel Cancer Center dive into the how and why behind targeted therapy, immunotherapy, and radiation therapy. Touching on improvements to... -
Finding Balance in Life and Treatment with Marnie Clark
The symptoms that led Marnie Clark to her doctor were unusual. Her leg was feeling “weird,” but it was more of an annoyance than something she was concerned about. Then came an... -
Building a Computational Model to Optimize Patient Treatment
Approximately 20%-35% of patients newly diagnosed with non-small cell lung cancer (NSCLC) will have locally advanced disease, sometimes referred to as stage III NSCLC. The... -
Clinical Trial Phases
The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes... -
Helpful Apps for People Living with Cancer
As mobile apps become more ingrained in our lives, it’s natural to look for ones that can help manage a cancer diagnosis. As for which app to choose, it really comes down to what... -
Repotrectinib is Now FDA-Approved to Treat Patients with ROS1-positive NSCLC
On November 15, 2023, the US Food and Drug Administration (FDA) announced the approval of repotrectinib to treat patients with locally advanced or metastatic ROS1-positive non... -
Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award
LUNGevity Foundation is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer. EGFR Resisters, a vibrant patient-led... -
LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards
LUNGevity Foundation is proud to announce the recipients of four awards to bolster the lung cancer research workforce— the Career Development Award, the VA Research Scholar Award... -
Finding (Mental) Peace this Holiday Season
The holidays are stressful enough without having to deal with lung cancer. LUNGevity is here to help. This discussion of the mental health challenges we face in the lung cancer... -
Treatment & Research Takeaways: ESMO 2023 Meeting
The European Society for Medical Oncology (ESMO) recently held its annual conference from October 20 – 24, 2023 in Madrid, Spain. ESMO represents one of the largest gatherings of...
Patient Gateway